Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-4443
Abstract: Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-1 (PD-L1) inhibition for rEAC.… read more here.
Keywords: feasibility; neoadjuvant chemoradiotherapy; resectable esophageal; esophageal adenocarcinoma ... See more keywords
The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "World Journal of Surgical Oncology"
DOI: 10.1186/s12957-018-1470-y
Abstract: BackgroundWe performed a meta-analysis to compare the efficacy of definitive chemoradiotherapy (dCRT) and esophagectomy as initial treatments for potentially resectable esophageal cancer.MethodsTo assess both strategies, the combined odds ratios (ORs) and 95% confidence intervals (CIs)… read more here.
Keywords: surgery; potentially resectable; initial treatments; treatments potentially ... See more keywords
Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Surgical Oncology"
DOI: 10.1245/s10434-019-08124-x
Abstract: Background The optimal treatment strategy for patients with borderline resectable (BR) esophageal squamous cell carcinoma (ESCC), in which tumors grow very close to the adjacent vital organs, remains unclear. This study evaluated the efficacy of… read more here.
Keywords: cell carcinoma; squamous cell; neoadjuvant chemoradiotherapy; resectable esophageal ... See more keywords
Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1041233
Abstract: Neoadjuvant chemoradiotherapy (NCRT) plus radical esophagectomy is currently the standard treatment for resectable esophageal or gastroesophageal junction (GEJ) carcinoma. The aim of this study is to evaluate the efficacy and safety of neoadjuvant immunotherapy in… read more here.
Keywords: neoadjuvant immunotherapy; resectable esophageal; efficacy safety; carcinoma ... See more keywords